


CLAIMS

We claim:

- 5 1. A compound of Formula I



I

wherein

- 10 Ar is phenyl optionally substituted with 1-3 substituents selected from the group consisting of halogen, C₁₋₆alkyl, and C₁₋₆alkoxy, or Ar is 2,3-dihydrobenzfuran-4-yl;

R¹ is C₁₋₆alkyl or phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C₁₋₆alkyl, and C₁₋₆alkoxy;

- 15 or Ar and R taken together with the carbon to which they are attached are 1-indanyl or 9-fluorenyl;

R², R³, R⁴, and R⁵ are independently hydrogen, halo, C₁₋₃alkoxy, or C₁₋₆alkyl;

- 20 or R² and R³ taken together, R³ and R⁴ taken together, or R⁴ and R⁵ taken together are -O(CH₂)₂₋₃- or -O(CH₂)₁₋₂O-; .

- R⁶ is selected from the group consisting of hydrogen, C₁₋₉alkyl, C₃₋₇cycloalkyl,
 25 C₁₋₆alkoxy, C₁₋₂perfluoroalkyl, -CH₂OC₁₋₃alkyl, -(CH₂)₁₋₂CO₂R⁷, -(CH₂)₁₋₂CO₂NR⁷₂,
 -NR⁷₂, -CH₂Cl, -CH₂OCOMe, -CH₂OPh, benzyl, 2-thienyl, 2-furanyl, 5-isoxazolyl,
 4-biphenyl, naphthyl, 4-(1,2-methylenedioxy)phenyl, and phenyl where phenyl is

optionally substituted with 1-3 substituents selected from halogen, C₁₋₃alkoxy, C₁₋₂perfluoroalkyl, C₁₋₂perfluoroalkoxy, and nitro; and

R⁷ is hydrogen or C₁₋₆alkyl;

5

or a stereoisomer, pharmaceutically acceptable salt, or solvate thereof.

2. The compound of claim 1 where Ar and R¹ are each phenyl optionally substituted with 1-3 substituents selected from halogen, C₁₋₆alkyl, and C₁₋₆alkoxy.

10

3. The compound of claim 2 where Ar is phenyl or 4-chlorophenyl and R¹ is phenyl.

4. The compound of claim 3 where R⁴ is C₁₋₃ alkoxy.

15

5. The compound of claim 4 selected from the group consisting of

1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbaldehyde;

20 1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;

1-[1-(2,2-diphenyl-ethyl)-6-bromo-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;


25 1-[1-(2,2-diphenyl-ethyl)-6-bromo-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-heptanone;

1-[1-(2-(4-chlorophenyl)-2-phenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;

30

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-propan-1-one;

- 1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-butan-1-one;
- 5 cyclopropyl-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-methanone;
- 10 1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-phenyl-methanone;
- 15 1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-2,2,2-trifluoro-ethanone;
- 20 1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid amide;
- 25 1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid methyl ester; and
- 30 1-[1-(2,2-diphenyl-ethyl)-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;
or a pharmaceutically acceptable salt or solvate thereof.
6. The compound of claim 3 where R³ and R⁴ taken together are -O(CH₂)₂₋₃₋ or -O(CH₂)₁₋₂O-.
7. A method of treatment for circadian-related disorders comprising
30 administration of a therapeutic amount of a compound of Formula Ia



where:

- 5 Ar is phenyl optionally substituted with 1-3 substituents selected from the group consisting of halogen, C₁₋₆alkyl, and C₁₋₆alkoxy, or Ar is 2,3-dihydrobenzfuran-4-yl;

R¹ is hydrogen, C₁₋₆alkyl, or phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C₁₋₆alkyl, and C₁₋₆alkoxy;

- 10 or Ar and R taken together with the carbon to which they are attached are 1-indanyl or 9-fluorenyl;

R², R³, R⁴, and R⁵ are independently hydrogen, halo, C₁₋₃alkoxy, or C₁₋₆alkyl;

- 15 or R² and R³ taken together, R³ and R⁴ taken together, or R⁴ and R⁵ taken together are -O(CH₂)₂₋₃- or -O(CH₂)₁₋₂O-;

- 20 R⁶ is selected from hydrogen, C₁₋₉alkyl, C₃₋₇cycloalkyl, C₁₋₆alkoxy, C₁₋₂perfluoroalkyl, -CH₂OC₁₋₃alkyl, -(CH₂)₁₋₂CO₂R⁷, -(CH₂)₁₋₂CO₂NR⁷₂, -NR⁷₂, -CH₂Cl, -CH₂OCOMe, -CH₂OPh, benzyl, 2-thienyl, 2-furanyl, 5-isoxazolyl, 4-biphenyl, naphthyl, 4-(1,2-methylenedioxy)phenyl, and phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C₁₋₃alkoxy, C₁₋₂perfluoroalkyl, C₁₋₂perfluoroalkoxy, and nitro; and

- 25 R⁷ is hydrogen or C₁₋₆alkyl;

or a stereoisomer, pharmaceutically acceptable salt, or solvate thereof.

8. A method of treating sleep disorders comprising administration of a therapeutic amount of the compound of claim 7.
9. A composition useful for treating a patient having circadian-related disorders comprising a therapeutic amount of a compound of claim 7 and a pharmaceutically acceptable carrier.
5
10. A composition useful for treating a patient having sleep disorders comprising a therapeutic amount of a compound of claim 7 and a pharmaceutically acceptable carrier.
10